resTORbio (NASDAQ:TORC) – Equities research analysts at Wedbush increased their Q1 2018 EPS estimates for shares of resTORbio in a report released on Tuesday, April 10th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.29) per share for the quarter, up from their previous estimate of ($0.34). Wedbush currently has a “Outperform” rating and a $30.00 target price on the stock. Wedbush also issued estimates for resTORbio’s Q2 2018 earnings at ($0.34) EPS, Q3 2018 earnings at ($0.39) EPS, Q4 2018 earnings at ($0.43) EPS, FY2018 earnings at ($1.45) EPS, Q1 2019 earnings at ($0.50) EPS, Q2 2019 earnings at ($0.55) EPS, Q3 2019 earnings at ($0.59) EPS, Q4 2019 earnings at ($0.60) EPS, FY2019 earnings at ($2.24) EPS, FY2020 earnings at ($2.32) EPS, FY2021 earnings at ($2.78) EPS and FY2022 earnings at ($1.30) EPS.
A number of other brokerages have also weighed in on TORC. Leerink Swann assumed coverage on resTORbio in a research report on Tuesday, February 20th. They set an “outperform” rating and a $36.00 target price on the stock. Evercore ISI assumed coverage on resTORbio in a research report on Tuesday, February 20th. They set an “outperform” rating and a $28.00 target price on the stock. Finally, Bank of America assumed coverage on resTORbio in a research report on Tuesday, February 20th. They set a “buy” rating and a $23.00 target price on the stock.
resTORbio (NASDAQ:TORC) last issued its earnings results on Thursday, March 29th. The company reported ($5.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.03) by ($4.08).
In related news, major shareholder Puretech Health Llc purchased 233,333 shares of the firm’s stock in a transaction that occurred on Tuesday, January 30th. The stock was acquired at an average price of $15.00 per share, for a total transaction of $3,499,995.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Orbimed Advisors Llc purchased 533,333 shares of the firm’s stock in a transaction that occurred on Tuesday, January 30th. The shares were bought at an average price of $15.00 per share, with a total value of $7,999,995.00. The disclosure for this purchase can be found here. Insiders have bought 768,666 shares of company stock worth $11,516,910 over the last ninety days.
ILLEGAL ACTIVITY NOTICE: This story was first published by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://dakotafinancialnews.com/2018/04/13/wedbush-comments-on-restorbios-q1-2018-earnings-torc.html.
resTORbio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems.
Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with MarketBeat.com's FREE daily email newsletter.